Should all pregnant women be given antimalarial drugs? Evidence update - Summary of a Cochrane Review by Effective Health Care Research Consortium
Evidence Update 
Maternal Health Series 
Inclusion criteria 
Studies:  
Randomized and quasi-randomized controlled trials.  
Participants: 
Pregnant women living in endemic malaria areas. 
Intervention: 
Interventions: drugs given to prevent clinical malaria, 
including regimens described as prophylaxis or 
presumptive treatment. 
Control: no regular or routine antimalarial drugs. 
Outcomes: 
Primary: maternal illness requiring hospitalisation; 
severe anaemia; perinatal death. 
Secondary: transfusion; anaemia; antenatal 
parasitaemia (mother). Placenta infected with malaria; 
mean birthweight; low birthweight; high birthweight; 
neonatal mortality (baby). 
Results 
• Sixteen trials including 12,638 women. Two trials 
were adequately concealed.  
• Antimalarials reduced antenatal parasitaemia when 
given to all pregnant women (relative risk 0.53, 
95% confidence interval 0.33 to 0.86; 328 women, 
2 trials). 
• In trials of routinely given antimalarial drugs in 
women having their first or second baby: 
- severe antenatal anaemia was less common 
(RR 0.62, 95% CI 0.50 to 0.78; 2809 women, 1 
prophylaxis and 2 IPT trials); 
- there were fewer perinatal deaths (RR 0.73, 
95% CI 0.53 to 0.99; 1986 participants, 2 
prophylaxis and 1 IPT trial);  
- mean birthweight was higher (WMD 126.7g, 
95% CI 88.64 to 164.7g; 2648 participants, 6 
prophylaxis and 2 IPT trials); 
- low birth weight was less common (RR 0.57, 
95% CI 0.46 to 0.72; 2350 participants, 4 
prophylaxis and 2 IPT trials). 
Should all pregnant women be given antimalarial drugs? 
In women in their first or second pregnancy, antimalarial drugs given routinely 
reduce severe anaemia in the mother and there are fewer perinatal deaths.  
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Authors’ conclusions 
Implications for practice:  
In intervention programmes for all pregnant women, routine antimalarial drugs reduce antenatal parasitaemia. 
In an analysis of low parity women, preventive treatment or drug prophylaxis is associated with fewer women 
with severe antenatal anaemia and antenatal parasitaemia. It is also associated with fewer perinatal deaths, 
higher mean birthweight, and fewer low birthweight infants. 
Implications for research: 
A large, simple trial implemented through routine health services could measure neonatal mortality. Such a 
study should compare prophylaxis (or presumptive treatment) with prompt regular treatment of morbidity. 
The Cochrane Database of Systematic Reviews is available from www.wiley.com, and free for eligible countries through www.healthinternetwork.org.  
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